CY1118388T1 - Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης - Google Patents
Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονηςInfo
- Publication number
- CY1118388T1 CY1118388T1 CY20161101349T CY161101349T CY1118388T1 CY 1118388 T1 CY1118388 T1 CY 1118388T1 CY 20161101349 T CY20161101349 T CY 20161101349T CY 161101349 T CY161101349 T CY 161101349T CY 1118388 T1 CY1118388 T1 CY 1118388T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- therapeutic agents
- subunits
- methods
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Περιγράφονται ενώσεις οι οποίες έχουν δραστικότητα μείωσης των επιπέδων της παραθορμόνης. Σε μία εφαρμογή, οι ενώσεις αποτελούνται από γειτονική αλληλουχία των υπομονάδων Χ1 - Χ2 - Χ3 - Χ4 - X5 - X6 - Χ7 , όπου η υπομονάδα Χ1 περιλαμβάνει ένα τμήμα το οποίο περιέχει θειόλη και η κατανομή του φορτίου των υπομονάδων Χ2 - Χ7 παρέχει την επιθυμητή δραστικότητα. Περιγράφονται επίσης μέθοδοι χρήσης των ενώσεων για την αγωγή του υπερπαραθυρεοειδισμού, της οστικής νόσου και/ή των διαταραχών, των υπερασβεστιαιμικών διαταραχών και συγκεκριμένα παρέχονται μέθοδοι για τη μείωση της ΡΤΗ εις το πλάσμα και του ασβεστίου εις τον ορό. Οι ενώσεις είναι δυνατόν να χρησιμοποιηθούν για την αγωγή υποκειμένων τα οποία έχουν, παραδείγματος χάριν: πρωτοπαθή, δευτεροπαθή ή τριτοπαθή υπερπαραθυρεοειδισμό· υπερασβεστιαιμία κακοήθειας, μεταστατική οστική νόσο ή οστεοπόρωση.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22969509P | 2009-07-29 | 2009-07-29 | |
US25581609P | 2009-10-28 | 2009-10-28 | |
US31363510P | 2010-03-12 | 2010-03-12 | |
PCT/US2010/043792 WO2011014707A2 (en) | 2009-07-29 | 2010-07-29 | Therapeutic agents for reducing parathyroid hormone levels |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1118388T1 true CY1118388T1 (el) | 2017-06-28 |
Family
ID=43527590
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20161101349T CY1118388T1 (el) | 2009-07-29 | 2016-12-27 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
CY2017010C CY2017010I1 (el) | 2009-07-29 | 2017-03-16 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
CY20191100579T CY1121922T1 (el) | 2009-07-29 | 2019-05-31 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2017010C CY2017010I1 (el) | 2009-07-29 | 2017-03-16 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
CY20191100579T CY1121922T1 (el) | 2009-07-29 | 2019-05-31 | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης |
Country Status (30)
Country | Link |
---|---|
US (10) | US8999932B2 (el) |
EP (5) | EP3808363B1 (el) |
JP (3) | JP5270799B2 (el) |
KR (1) | KR101781841B1 (el) |
CN (2) | CN102711789B (el) |
AU (1) | AU2010278897B2 (el) |
BR (1) | BR112012002143B8 (el) |
CA (1) | CA2769525C (el) |
CY (3) | CY1118388T1 (el) |
DK (2) | DK2459208T3 (el) |
ES (2) | ES2607954T3 (el) |
FR (1) | FR17C1009I2 (el) |
HK (1) | HK1167108A1 (el) |
HR (2) | HRP20161614T1 (el) |
HU (3) | HUE043838T2 (el) |
IL (1) | IL217749A (el) |
LT (3) | LT2459208T (el) |
LU (1) | LUC00008I2 (el) |
MX (1) | MX2012001213A (el) |
NO (1) | NO2017021I1 (el) |
NZ (1) | NZ597922A (el) |
PL (2) | PL3192520T3 (el) |
PT (2) | PT3192520T (el) |
RU (1) | RU2557654C3 (el) |
SG (2) | SG178143A1 (el) |
SI (2) | SI2459208T1 (el) |
SM (1) | SMT201700014B (el) |
TW (1) | TWI520744B (el) |
WO (1) | WO2011014707A2 (el) |
ZA (1) | ZA201200726B (el) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008067199A2 (en) * | 2006-11-16 | 2008-06-05 | Kai Pharmaceuticals, Inc. | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders |
PL3192520T3 (pl) | 2009-07-29 | 2019-08-30 | Kai Pharmaceuticals, Inc. | Środki lecznicze do zmniejszania poziomów parathormonu |
EP2543660A4 (en) | 2010-03-04 | 2014-04-30 | Ajinomoto Kk | PROPHYLACTIC OR THERAPEUTIC ACTIVE AGAINST DIABETES OR ADIPOSITAS |
CN102781910B (zh) | 2010-03-04 | 2015-03-11 | 味之素株式会社 | 烷基胺衍生物 |
WO2011118843A1 (ja) | 2010-03-24 | 2011-09-29 | 味の素株式会社 | グルタミン酸エステル誘導体又はその塩 |
EP2554165A4 (en) | 2010-04-02 | 2014-04-30 | Ajinomoto Kk | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY |
BR112013031539A2 (pt) * | 2011-06-08 | 2019-07-30 | Kai Pharmaceuticals Inc | agentes terapêuticos para regular fósforo sérico |
AU2012335009B2 (en) * | 2011-11-10 | 2017-08-31 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
JP2015514771A (ja) * | 2012-04-17 | 2015-05-21 | ブラウン ユニバーシティ | 神経保護性組成物および使用方法 |
US20200354428A9 (en) | 2013-06-23 | 2020-11-12 | Wisconsin Alumni Research Foundation | Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles |
CA2916222C (en) | 2013-06-28 | 2021-05-18 | Amgen Inc. | Stable liquid formulation of amg 416 (etelcalcetide) |
DK3126373T3 (da) * | 2014-04-03 | 2020-05-04 | Amgen Inc | Fremgangsmåde til fremstilling af amg 416 |
CN105504012A (zh) * | 2014-09-30 | 2016-04-20 | 深圳翰宇药业股份有限公司 | 一种多肽的制备方法 |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
EP3220961B1 (en) | 2014-10-22 | 2023-07-05 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
EP3274360B1 (en) * | 2015-03-26 | 2020-05-06 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
US9336841B1 (en) * | 2015-04-16 | 2016-05-10 | Taiwan Semiconductor Manufacturing Co., Ltd. | Pipeline register with data alignment therein |
CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
WO2018044468A1 (en) * | 2016-08-30 | 2018-03-08 | Wisconsin Alumni Research Foundation | COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM |
US20200261549A1 (en) * | 2017-11-07 | 2020-08-20 | Alphacore Pharma Llc | Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms |
WO2019124411A1 (ja) | 2017-12-20 | 2019-06-27 | Eaファーマ株式会社 | 維持透析下の二次性副甲状腺機能亢進症の予防または治療用医薬組成物 |
KR20210124958A (ko) * | 2018-11-02 | 2021-10-15 | 앰퍼샌드 바이오파마슈티컬스, 인코포레이티드 | 국소적으로 적용되는 완충제(buffers)를 사용하는 양이온 과부하 및 전해질 불균형의 위험 가능성 관리를 위한 제형 및 방법 |
US20220142958A1 (en) | 2019-04-03 | 2022-05-12 | Ea Pharma Co., Ltd. | Medicinal composition having excellent stability |
KR20220110789A (ko) * | 2019-12-09 | 2022-08-09 | 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 | 칼슘 감지 수용체 효능제 화합물 및 이의 응용 |
US20230223125A1 (en) * | 2020-05-04 | 2023-07-13 | University Of Louisville Research Foundation, Inc. | Artificial intelligence-based systems and methods for dosing of pharmacologic agents |
WO2022052471A1 (zh) * | 2020-09-10 | 2022-03-17 | 陕西麦科奥特科技有限公司 | 双特异性融合多肽化合物 |
US11359134B2 (en) | 2020-10-19 | 2022-06-14 | Saudi Arabian Oil Company | Treatment fluids and methods for recovering hydrocarbons from a subterranean formation |
CN117500820A (zh) * | 2021-06-08 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
EP4353248A1 (en) * | 2021-06-08 | 2024-04-17 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Calcium-sensing receptor agonist composition and application thereof |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
AU9131091A (en) | 1990-11-07 | 1992-06-11 | Scripps Research Institute, The | Peptides that inhibit platelet binding of adhesion molecules |
US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
CA2145214A1 (en) | 1995-02-28 | 1996-08-29 | Rick E. Preddie | Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5688489A (en) | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
DE69734157T2 (de) | 1996-07-31 | 2006-07-13 | The General Hospital Corp., Boston | Parathyroidhormon-verwandthe peptidanaloge |
US5895368A (en) | 1996-09-23 | 1999-04-20 | Medisystems Technology Corporation | Blood set priming method and apparatus |
WO1998017299A1 (en) | 1996-10-18 | 1998-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase c, methods and compositions |
WO1998033812A1 (en) | 1997-02-05 | 1998-08-06 | Brigham And Women's Hospital, Inc. | Mast cell protease peptide inhibitors |
UA62967C2 (en) * | 1997-05-14 | 2004-01-15 | Aventis Pharm Prod Inc | Peptide analogs of parathyroid hormons |
GB2341390B (en) * | 1997-05-21 | 2000-11-08 | Univ Leland Stanford Junior | Composition and method for enhancing transport across biological membranes |
US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
JP2000336099A (ja) | 1999-05-27 | 2000-12-05 | Sekisui Chem Co Ltd | ペプチド及びc型肝炎抗体検出用試薬 |
US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
US20020068342A1 (en) * | 2000-02-09 | 2002-06-06 | Rami Khosravi | Novel nucleic acid and amino acid sequences and novel variants of alternative splicing |
JP2004504295A (ja) | 2000-07-18 | 2004-02-12 | ボーン ケア インターナショナル インコーポレイテッド | 安定化1α−ヒドロキシビタミンD |
DE10041126A1 (de) * | 2000-08-22 | 2002-04-04 | Aventis Res & Tech Gmbh & Co | DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen |
US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
US20020168354A1 (en) | 2000-11-10 | 2002-11-14 | Daria Mochly-Rosen | psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia |
CA2434643C (en) | 2001-01-18 | 2013-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of.delta.pkc |
US20030091640A1 (en) | 2001-02-08 | 2003-05-15 | Srinivasan Ramanathan | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents |
US20030036627A1 (en) | 2001-02-16 | 2003-02-20 | Montelaro Ronald C. | Virus derived antimicrobial peptides |
CA2439178C (en) | 2001-02-23 | 2013-06-04 | Polyphor Ltd. | Template-fixed peptidomimetics with antimicrobial activity |
US6790833B2 (en) * | 2001-08-08 | 2004-09-14 | The Research Foundation Of The State University Of New York | Antifungal and antibacterial agents |
WO2003013543A1 (en) | 2001-08-08 | 2003-02-20 | Genomed, Llc | Treatment or prevention of acute renal failure |
US7060023B2 (en) | 2001-09-25 | 2006-06-13 | The Foundry Inc. | Pericardium reinforcing devices and methods of using them |
JP2005287302A (ja) | 2002-04-03 | 2005-10-20 | Haruhiko Fujiwara | ポリペプチドの架橋方法 |
US20040018976A1 (en) | 2002-05-14 | 2004-01-29 | Feder John N. | Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof |
ATE377023T1 (de) | 2003-11-05 | 2007-11-15 | Pevion Biotech Ltd | Zusammensetzungen, die von melittin abgeleitet sind und peptide enthalten, und verfahren zur potenzierung von immunreaktionen gegen target- antigene |
KR20070004571A (ko) | 2003-12-11 | 2007-01-09 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 단백질 키나제 c의 동종효소-특이적 길항제 |
WO2005072340A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
US20060052303A1 (en) * | 2004-07-27 | 2006-03-09 | Sampath Kuber T | Use of thyrotropin for regeneration of bone |
US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
DE102005013846A1 (de) | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
KR100687932B1 (ko) * | 2005-08-09 | 2007-02-27 | 삼성전자주식회사 | 영상표시장치 및 영상표시방법 |
WO2007027510A2 (en) * | 2005-08-30 | 2007-03-08 | Acologix, Inc. | Regulation of mineral and skeletal metabolism |
WO2008067199A2 (en) * | 2006-11-16 | 2008-06-05 | Kai Pharmaceuticals, Inc. | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders |
KR101775929B1 (ko) | 2007-01-19 | 2017-09-07 | 카이 파마슈티컬즈 | 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형 |
EP2197495A2 (en) | 2007-10-02 | 2010-06-23 | MDRNA, Inc. | Lipopeptides for delivery of nucleic acids |
US8716437B2 (en) | 2007-12-07 | 2014-05-06 | Steven A. Goldstein | Identification of toxin ligands |
US20090318351A1 (en) * | 2008-03-12 | 2009-12-24 | Kevin Grimes | Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist |
PL3192520T3 (pl) | 2009-07-29 | 2019-08-30 | Kai Pharmaceuticals, Inc. | Środki lecznicze do zmniejszania poziomów parathormonu |
BR112013031539A2 (pt) | 2011-06-08 | 2019-07-30 | Kai Pharmaceuticals Inc | agentes terapêuticos para regular fósforo sérico |
AU2012335009B2 (en) | 2011-11-10 | 2017-08-31 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
-
2010
- 2010-07-29 PL PL16190682T patent/PL3192520T3/pl unknown
- 2010-07-29 SM SM201700014T patent/SMT201700014B/it unknown
- 2010-07-29 US US12/846,724 patent/US8999932B2/en active Active
- 2010-07-29 KR KR1020127004785A patent/KR101781841B1/ko active IP Right Grant
- 2010-07-29 HU HUE16190682A patent/HUE043838T2/hu unknown
- 2010-07-29 WO PCT/US2010/043792 patent/WO2011014707A2/en active Application Filing
- 2010-07-29 PT PT16190682T patent/PT3192520T/pt unknown
- 2010-07-29 HU HUE10805078A patent/HUE030960T2/en unknown
- 2010-07-29 NZ NZ597922A patent/NZ597922A/en unknown
- 2010-07-29 DK DK10805078.2T patent/DK2459208T3/en active
- 2010-07-29 SG SG2012006185A patent/SG178143A1/en unknown
- 2010-07-29 EP EP20209086.6A patent/EP3808363B1/en active Active
- 2010-07-29 AU AU2010278897A patent/AU2010278897B2/en active Active
- 2010-07-29 BR BR112012002143A patent/BR112012002143B8/pt active IP Right Grant
- 2010-07-29 LT LTEP10805078.2T patent/LT2459208T/lt unknown
- 2010-07-29 LT LTEP16190682.1T patent/LT3192520T/lt unknown
- 2010-07-29 MX MX2012001213A patent/MX2012001213A/es active IP Right Grant
- 2010-07-29 EP EP22193946.5A patent/EP4154900A1/en active Pending
- 2010-07-29 EP EP10805078.2A patent/EP2459208B1/en active Active
- 2010-07-29 PL PL10805078T patent/PL2459208T3/pl unknown
- 2010-07-29 SI SI201031337A patent/SI2459208T1/sl unknown
- 2010-07-29 RU RU2012107428A patent/RU2557654C3/ru active
- 2010-07-29 CN CN201080045024.9A patent/CN102711789B/zh active Active
- 2010-07-29 TW TW099125105A patent/TWI520744B/zh active
- 2010-07-29 DK DK16190682.1T patent/DK3192520T3/da active
- 2010-07-29 SG SG10201406921SA patent/SG10201406921SA/en unknown
- 2010-07-29 PT PT108050782T patent/PT2459208T/pt unknown
- 2010-07-29 ES ES10805078.2T patent/ES2607954T3/es active Active
- 2010-07-29 CA CA2769525A patent/CA2769525C/en active Active
- 2010-07-29 EP EP16190682.1A patent/EP3192520B1/en active Active
- 2010-07-29 SI SI201031894T patent/SI3192520T1/sl unknown
- 2010-07-29 ES ES16190682T patent/ES2729051T3/es active Active
- 2010-07-29 EP EP19159337.5A patent/EP3539555B1/en active Active
- 2010-07-29 CN CN201710873189.9A patent/CN107674114B/zh active Active
- 2010-07-29 JP JP2012523061A patent/JP5270799B2/ja active Active
-
2012
- 2012-01-26 IL IL217749A patent/IL217749A/en active Protection Beyond IP Right Term
- 2012-01-30 ZA ZA2012/00726A patent/ZA201200726B/en unknown
- 2012-02-02 US US13/365,213 patent/US8377880B2/en active Active
- 2012-08-14 HK HK12107946.6A patent/HK1167108A1/zh unknown
-
2013
- 2013-02-18 US US13/769,744 patent/US9278995B2/en active Active
- 2013-05-09 JP JP2013099331A patent/JP5764613B2/ja active Active
-
2014
- 2014-02-10 JP JP2014023488A patent/JP2014094967A/ja active Pending
-
2015
- 2015-03-04 US US14/639,020 patent/US9567370B2/en active Active
-
2016
- 2016-02-08 US US15/018,567 patent/US9701712B2/en active Active
- 2016-12-01 HR HRP20161614TT patent/HRP20161614T1/hr unknown
- 2016-12-27 CY CY20161101349T patent/CY1118388T1/el unknown
-
2017
- 2017-01-09 US US15/402,133 patent/US20170114095A1/en not_active Abandoned
- 2017-03-01 HU HUS1700008 patent/HUS1700008I1/hu unknown
- 2017-03-09 LU LU00008C patent/LUC00008I2/fr unknown
- 2017-03-10 LT LTPA2017007C patent/LTC2459208I2/lt unknown
- 2017-03-16 CY CY2017010C patent/CY2017010I1/el unknown
- 2017-03-17 FR FR17C1009C patent/FR17C1009I2/fr active Active
- 2017-05-05 NO NO2017021C patent/NO2017021I1/no unknown
- 2017-06-21 US US15/629,536 patent/US10280198B2/en active Active
-
2019
- 2019-03-11 US US16/298,902 patent/US20190194252A1/en not_active Abandoned
- 2019-05-17 HR HRP20190923TT patent/HRP20190923T1/hr unknown
- 2019-05-31 CY CY20191100579T patent/CY1121922T1/el unknown
-
2020
- 2020-09-02 US US17/010,773 patent/US20200399309A1/en not_active Abandoned
-
2022
- 2022-10-04 US US17/960,060 patent/US20240116983A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1118388T1 (el) | Θεραπευτικοι παραγοντες για τη μειωση των επιπεδων παραθορμονης | |
CL2017003288A1 (es) | Métodos para tratar o prevenir enfermedades relacionadas con el colesterol (divisional solicitud 201303214) | |
CY1119893T1 (el) | Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων | |
CO7240399A2 (es) | Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos | |
PH12019500296A1 (en) | Amino pyrimidine ssao inhibitors | |
CO2018010475A2 (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
UY36458A (es) | Anticuerpos humanos para hemaglutinina influenza. | |
EA201992063A1 (ru) | СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1 | |
WO2008067199A3 (en) | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders | |
CR20190071A (es) | Compuestos, composiciones y métodos para el tratamiento de enfermedades | |
MX2015017961A (es) | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. | |
PA8804901A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo | |
BR112016022742A2 (pt) | composições e métodos para modular a expressão de receptor de hormônio do crescimento | |
CR20210508A (es) | COMPUESTOS y COMPOSICIONES PARA EL TRATAMIENTO DE ENFERMEDAD | |
EA201290322A1 (ru) | Лечение желудочно-кишечных расстройств | |
BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
MX2022002056A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
UY29962A1 (es) | Compuestos calciliticos | |
EA202091559A1 (ru) | Способ получения модуляторов соматостатина | |
CR11562A (es) | Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina | |
CL2019001749A1 (es) | Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta. | |
BR112018074941A2 (pt) | combinações farmacêuticas | |
BR112017003332A2 (pt) | uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica | |
CY1123861T1 (el) | Θεραπευτικη αντιμετωπιση εξαψεων και οστικης απωλειας, επαγομενων απο θεραπεια στερησης ανδρογονων, με χρηση cis-κλομιφαινης | |
CY1119819T1 (el) | Παραθυρεοειδης ορμονη (ρτη) για χρηση στην θεραπεια ισχαιμιας |